MyoKardia, Inc. (MYOK)
| Market Cap | 11.99B |
| Revenue (ttm) | 12.40M |
| Net Income (ttm) | -276.96M |
| Shares Out | 53.10M |
| EPS (ttm) | -5.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Nov 17, 2021 |
| Last Price | $224.91 |
| Previous Close | $224.91 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 224.52 - 225.00 |
| Day's Volume | 0 |
| 52-Week Range | 42.65 - 225.00 |
News
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients
Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy Regis...
Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receiv...
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodi...
EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation
MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MyoKardia, Inc. (NASDAQ: MYOK) concerning potential violations of th...
NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...
Cardiovascular drugs have been unsuccessful investments in recent years, but this one makes sense.
Myokardia Inc (NASDAQ: MYOK) announced Monday a definitive agreement to be bought by Bristol-Myers Squibb Co (NYSE: BMY). The Myokardia Analysts: Wedbush analyst David Nierengarten downgraded ...
After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.
NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MyoKardia, Inc. ("MYOK" or the...
"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.
Bristol-Myers Squibb CEO on $13 billion MyoKardia acquisition: 'potentially revolutionary medicine'
"MyoKardia is an important company" with an "interesting approach to the treatment of cardiovascular disease, which is a precision approach," Bristol-Myers Squibb CEO Giovanni Caforio said.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of MyoKardia, Inc. (NASDAQ: MYOK) to Bristol-Myers Squibb Company for $225.50 ...
MyoKardia's major, $13.1 billon deal with fellow pharmaceutical company Bristol Myers Squibb sent MYOK stock soaring on Monday. The post M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers...
The transaction will give Bristol Myers Squibb a potential first-in-class cardiovascular drug with blockbuster expectations.
Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.
New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...
MyoKardia Inc. (NASDAQ: MYOK) shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb Co.
Bristol Myers Squibb said it reached an agreement to acquire MyoKardia for $13.1 billion, adding to its portfolio of treatments for cardiovascular diseases but sending BMY stock down early. Th...
The heart disease specialist fetches a rather rich buyout offer from Bristol Myers Squibb.
Pharma giant Bristol-Myers Squibb Co (NYSE: BMY) is bulking up, as the company announced a multi-billion dollar deal to buy cardio-focused biopharma Myokardia Inc (NASDAQ: MYOK). Deal Terms: B...
In an announcement on Monday, Bristol Myers Squibb Co (NYSE: BMY) said it will invest £10 billion to acquire MyoKardia Inc (Nasdaq: MYOK). The deal, it added, will help it expand its footprint...
SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of MyoKardia, Inc. ("MyoKardia" or the "Com...
Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on ca...
Shares of MyoKardia Inc. MYOK, -0.36% soared 57% toward a record high in premarket trading Monday, after the biotechnology company confirmed that it agreed to be bought out by Bristol Myers Sq...
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb...
BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamti...
Myokardia CEO talk about its new trial data to treat heart disease
Myokardia develops therapies and treatments for inherited heart conditions, particularly hypertrophic cardiomyopathy or HCM, which affects 650,000 people in the U.S.
EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet
It's not uncommon for stocks that have significantly outperformed for several months to take a breather.
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM
Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31 Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31
BRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcar...
MyoKardia, Inc. (MYOK) CEO Tassos Gianakakos on Q2 2020 Results - Earnings Call Transcript
BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.
VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy VALOR-HCM Designed to Generate Direct Evidenc...
VALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy VALOR-HCM Designed to Generate Direct Evidenc...
BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2...
BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designati...
BRISBANE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick ...
MyoKardia's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction
-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that dat...
BRISBANE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the...
About MYOK
MyoKardia, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyo... [Read more...]
| Industry Biotechnology | IPO Date Oct 29, 2015 |
| CEO Anastasios E. Gianakakos | Employees 318 |
| Stock Exchange NASDAQ | Ticker Symbol MYOK |